Comparison of efficacy and safety of the secondary treatment with increased fesoterodine and with mirabegron combination with 4mg fesoterodine for those who still have moderate or more overactive bladder symptoms after the initial treatment with 4mg fesoterodine: preliminary study
Not Applicable
- Conditions
- overactive bladder
- Registration Number
- JPRN-UMIN000011677
- Lead Sponsor
- Dept. of Urology, Otsu Minicipal Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with the practice of catheterization past or present. 2) Residual urine volume is more than 100ml. 3) Patients who can`t urine voluntarily. 4) Neurogenic bladder, urethral stricture, urinary tract infection, urinary tract calculi, interstitial cystitis, chronic prostatitis, prostate cancer, bladder cancer 5) Patients who are contraindicated for fesoterodine administration. 6) Patients who are contraindicated for mirabegron administration. 7) Patients who have the history of the administration of contraindicated agents within 2 weeks.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method